(NASDAQ: ACRS) Aclaris Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Diagnostics & Research industry's average forecast earnings growth rate of 17.56%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 33.74%.
Aclaris Therapeutics's earnings in 2026 is -$64,923,000.On average, 11 Wall Street analysts forecast ACRS's earnings for 2026 to be -$70,966,132, with the lowest ACRS earnings forecast at -$92,375,151, and the highest ACRS earnings forecast at -$54,606,000. On average, 10 Wall Street analysts forecast ACRS's earnings for 2027 to be -$74,964,071, with the lowest ACRS earnings forecast at -$83,880,884, and the highest ACRS earnings forecast at -$50,857,255.
In 2028, ACRS is forecast to generate -$88,962,276 in earnings, with the lowest earnings forecast at -$110,425,468 and the highest earnings forecast at -$36,404,000.